Abstract
Over the years, accumulating evidence has indicated that D-serine represents the endogenous ligand for the glycinemodulatory binding site on the NR1 subunit of N-methyl-D-aspartate receptors in various brain areas. Cellular concentrations of D-serine are regulated by synthesis due to the enzyme serine racemase (isomerization reaction) and by degradation due to the same enzyme (elimination reaction) as well as by the FAD-containing flavoenzyme D-amino acid oxidase (DAAO, oxidative deamination reaction). Several findings have linked low levels of D-serine to schizophrenia: D-serine concentrations in serum and cerebrospinal fluid have been reported to be decreased in schizophrenia patients while human DAAO activity and expression are increased; oral administration of Dserine improved positive, negative, and cognitive symptoms of schizophrenia as add-on therapy to typical and atypical antipsychotics. This evidence indicates that increasing NMDA receptor function, perhaps by inhibiting DAAO-induced degradation of D-serine may alleviate symptoms in schizophrenic patients. Furthermore, it has been suggested that co-administration of D-serine with a human DAAO inhibitor may be a more effective means of increasing D-serine levels in the brain. Here, we present an overview of the current knowledge of the structure-function relationships in human DAAO and of the compounds recently developed to inhibit its activity (specifically the ones recently exploited for schizophrenia treatment).
Keywords: Schizophrenia, D-serine, NMDA receptor, inhibitors
Current Pharmaceutical Design
Title:D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy
Volume: 19 Issue: 14
Author(s): Silvia Sacchi, Elena Rosini, Loredano Pollegioni and Gianluca Molla
Affiliation:
Keywords: Schizophrenia, D-serine, NMDA receptor, inhibitors
Abstract: Over the years, accumulating evidence has indicated that D-serine represents the endogenous ligand for the glycinemodulatory binding site on the NR1 subunit of N-methyl-D-aspartate receptors in various brain areas. Cellular concentrations of D-serine are regulated by synthesis due to the enzyme serine racemase (isomerization reaction) and by degradation due to the same enzyme (elimination reaction) as well as by the FAD-containing flavoenzyme D-amino acid oxidase (DAAO, oxidative deamination reaction). Several findings have linked low levels of D-serine to schizophrenia: D-serine concentrations in serum and cerebrospinal fluid have been reported to be decreased in schizophrenia patients while human DAAO activity and expression are increased; oral administration of Dserine improved positive, negative, and cognitive symptoms of schizophrenia as add-on therapy to typical and atypical antipsychotics. This evidence indicates that increasing NMDA receptor function, perhaps by inhibiting DAAO-induced degradation of D-serine may alleviate symptoms in schizophrenic patients. Furthermore, it has been suggested that co-administration of D-serine with a human DAAO inhibitor may be a more effective means of increasing D-serine levels in the brain. Here, we present an overview of the current knowledge of the structure-function relationships in human DAAO and of the compounds recently developed to inhibit its activity (specifically the ones recently exploited for schizophrenia treatment).
Export Options
About this article
Cite this article as:
Sacchi Silvia, Rosini Elena, Pollegioni Loredano and Molla Gianluca, D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy, Current Pharmaceutical Design 2013; 19 (14) . https://dx.doi.org/10.2174/1381612811319140002
DOI https://dx.doi.org/10.2174/1381612811319140002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Integration of Cognitive Tests and Resting State fMRI for the Individual Identification of Mild Cognitive Impairment
Current Alzheimer Research Utilizing Ultrasound to Transiently Increase Blood-Brain Barrier Permeability, Modulate of the Tight Junction Proteins, and Alter Cytoskeletal Structure
Current Neurovascular Research ApoE ε4 Allele Related Alterations in Hippocampal Connectivity in Early Alzheimer’s Disease Support Memory Performance
Current Alzheimer Research Impact of Nutrients on the Functioning of Intestinal Goblet Cells: Health and Therapeutic Perspectives
Current Nutrition & Food Science Role of Galectins in Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Proteomics of Human Pulmonary Surfactant Proteins
Current Proteomics Bioactive Food Components as Dietary Intervention for Cystic Fibrosis
Current Drug Targets High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Factors Affecting the Age at Menarche in High School Students in the West of Iran
Current Women`s Health Reviews Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Genetics and Mitochondrial Abnormalities in Autism Spectrum Disorders:A Review
Current Genomics Editorial [Hot topic: Immunological Regulation of the Central Nervous System: From Physiological to Pathological Processes (Guest Editor: Oscar Gonzalez-Perez)]
Current Immunology Reviews (Discontinued) NOX3-Targeted Therapies for Inner Ear Pathologies
Current Pharmaceutical Design Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Inflammation, Adipocytokines, and Atherosclerosis in the Metabolic Syndrome
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Exploring and Exploiting Microbial Diversity through Metagenomics for Natural Product Drug Discovery
Current Topics in Medicinal Chemistry